Study Shows Cardioscan Leads to 41% Reduction of Unnecessary and Costly Cardiac Referrals by Physicians
09 October 2006 - 11:00PM
PR Newswire (US)
Study Also Credits Cardioscan with Aiding Physicians in Improving
Detection of Murmurs Associated with Potentially Harmful Heart
Disease by 46% PRINCETON, N.J., Oct. 9 /PRNewswire/ -- Zargis
Medical Corp., a spin-off from Siemens Corporate Research (NYSE:SI)
and a majority-owned subsidiary of Speedus Corp. (NASDAQ:SPDE),
today announced summary results of the clinical study it conducted
in 2005 in collaboration with The Johns Hopkins University School
of Medicine. The study assessed the impact of the Cardioscan(R)
system on referral decisions made by primary care physicians
regarding heart murmurs -- which are potential signs of heart
disease. An abstract from the study was presented at the American
Academy of Pediatrics National Conference & Exhibition
yesterday in Atlanta. The study measured the accuracy of a group of
primary care physicians in evaluating a set of 100 recorded heart
sounds. The heart sounds were independently evaluated by each
physician both with and without access to Cardioscan's reported
findings. With Cardioscan's findings, the physicians were able to
reduce their rates of unnecessary referrals by an average of 41%.
This indicates Cardioscan's potential to generate a large reduction
in wasted healthcare spending. The study also revealed a reduction
in the physicians' false negative rates by an average of 46%,
suggesting that Cardioscan could increase a physician's ability to
identify those pathological heart conditions that are difficult to
detect with a standard stethoscope. "In addition to the medical
benefits that would result from improving the diagnostic accuracy
of heart sound evaluation, strong financial incentives exist as
well. We estimate that more than 3 million U.S. patients are
unnecessarily referred each year for an echocardiogram or to a
heart specialist for evaluation of innocent heart murmurs. Based on
the results of this study, we are confident that Cardioscan can
contribute to a significant reduction in this unnecessary
healthcare spending while dramatically improving a physician's
ability to detect potentially pathological heart murmurs," stated
Zargis CEO John Kallassy. Zargis will be presenting the financial
and medical benefits of Cardioscan usage suggested by this study to
health insurance providers and other organizations that may benefit
from Zargis' technology. About Zargis Medical Corp. Zargis Medical
Corp. develops advanced diagnostic decision support products and
services for primary care physicians, pediatricians, cardiologists
and other healthcare professionals. Zargis was formed in 2001 when
Siemens Corporate Research, a division of Siemens AG (NYSE:SI), and
Speedus Corp. co-invested to develop and market an advanced
acoustic technology designed to detect heart abnormalities
identified through analysis of heart sounds. About Cardioscan
Zargis has developed Cardioscan, the first and only
computer-assisted medical device designed to support physicians in
analyzing heart sounds for the identification of suspected systolic
and diastolic murmurs. Cardioscan is a non-invasive device that is
easy to use, portable, and takes just minutes to perform. The
device implements voice-guided protocol and a graphical user
interface while maintaining an efficient physician workflow.
Cardioscan provides a summary of findings in terms that are readily
understood by physicians and offers an additional range of
quantitative auscultatory information that cannot be obtained
through listening alone. As a result, Cardioscan enhances
auscultation-a procedure that has been universally employed through
a stethoscope for nearly two-hundred years. For additional
information about Zargis or Speedus Corp., contact Peter Hodge at
888.773.3669 (ext. 23) or or visit the following Web sites:
http://www.zargis.com/ and http://www.speedus.com/. Statements
contained herein that are not historical facts, including but not
limited to statements about the Company's product, corporate
identity and focus, may be forward-looking statements that are
subject to a variety of risks and uncertainties. There are a number
of important factors that could cause actual results to differ
materially from those expressed in any forward-looking statements
made by the Company, including, but not limited to, the continuing
development of the Company's sales, marketing and support efforts.
DATASOURCE: Zargis Medical Corp. CONTACT: Peter Hodge of Zargis
Medical Corp., 1-888-773-3669 ext. 23, Web site:
http://www.zargis.com/ http://www.speedus.com/
Copyright
Speedus (CE) (USOTC:SPDE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Speedus (CE) (USOTC:SPDE)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Speedus Corp (CE) (OTCMarkets): 0 recent articles
More Speedus (MM) News Articles